Revagenix Inc.
San Mateo, CA Doing business as Revagenix Inc. Revagenix, Inc.
- UEI
- D98QFZUPFXJ9
- CAGE
- 8B1Y9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1729 Dolan Ave, San Mateo, CA 94401, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A novel lpxc inhibitor with pan-resistant pseudomonas and burkholderia activity. | National Institute of Allergy and Infectious Diseases | $28,167,401 | |
| To select a novel small molecule antibiotic for clinical development and advance IT through IND filing and phase 1… | National Institute of Allergy and Infectious Diseases | $26,944,787 |
Quick answers
What is Revagenix Inc.'s UEI?
Revagenix Inc.'s Unique Entity ID (UEI) in SAM.gov is D98QFZUPFXJ9.
What is Revagenix Inc.'s CAGE code?
Revagenix Inc.'s CAGE code is 8B1Y9.
What is Revagenix Inc.'s primary NAICS code?
Revagenix Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Revagenix Inc. located?
Revagenix Inc.'s physical address in SAM.gov is 1729 Dolan Ave, San Mateo, CA 94401, USA.
Is Revagenix Inc. registered in SAM.gov?
Yes. Revagenix Inc.'s SAM.gov registration is active through January 28, 2027.
What is Revagenix Inc.'s most recent federal award?
Revagenix Inc.'s most recent federal contract award is A novel lpxc inhibitor with pan-resistant pseudomonas and burkholderia activity (75N93022C00061), from National Institute of Allergy and Infectious Diseases, on September 22, 2022.
On GovTribe
See Revagenix Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors